
For years, Innohep has been the cornerstone of Leo Pharma’s product portfolio and, although skin diseases is the professed main area of the company, the size of the product has helped create a sizeable business in the anticoagulant area, to which Innohep belongs, says EVP of Global Sales & Marketing, Lars Olsen.
For a number of years, Leo Pharma has been marketing the injection drug, Innohep, for prophylactic blood clots as well as blood clots in the legs and lungs, but with approval of a new indication in France the market potential could be significantly expanded.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app